Statistically significant differences in PFS were observed among all G4 astrocytomas that expressed PRMT5 and received either TMZ or TMZ plus other chemotherapies, regardless of their IDH or MGMT-promoter methylation status (p-value = 0.0014) (Fig. 3). The gene discussed is PRMT5; the disease is astrocytoma (excluding glioblastoma).